PETIZATION

Biological preparations for pharmaceutical purposes for the treatment of pain, itch, diabetes, cancer, and inflammation; pharmaceutical preparations for the treatment of pain, itch, diabetes, cancer, and inflammation; pharmaceutical preparations for animals for the treatment of pain, itch, diabetes, cancer, and inflammation; pharmaceutical preparations for veterinary use for the treatment of pain, itch, diabetes, cancer, and inflammation; radioactive preparations for veterinary use for the treatment of pain, itch, diabetes, cancer, and inflammation; reagents for in-vitro laboratory use for medical diagnostic veterinary purposes; reagents for laboratory purposes for medical diagnostic veterinary purposes; reagents for use in analytical tests for medical diagnostic veterinary purposes; reagents for use in diagnostic tests for medical diagnostic veterinary purposes; reagents for use in the development of monoclonal antibodies for medical diagnostic veterinary purposes; reagents in kit form for conducting enzyme-linked immunosorbent assays (ELISA) for medical diagnostic veterinary purposes; veterinary preparations for the treatment of pain, itch, diabetes, cancer, and inflammation; veterinary preparations for administration by injection for the treatment of pain, itch, diabetes, cancer, and inflammation; veterinary preparations for immunisation against disease; veterinary preparations for use in improving the skin; veterinary preparations for use in treating the coat; veterinary preparations in dosage forms for veterinary use for the treatment of pain, itch, diabetes, cancer, and inflammation; veterinary products, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues; veterinary products for equines, namely, fully equinized monoclonal antibodies, equine fusion proteins; veterinary vaccines; biological preparations for veterinary purposes for the treatment of pain, itch, diabetes, cancer, and inflammation; antibodies for pain, itch, diabetes, cancer, and inflammation; immunological antibodies for medical use for the treatment of cancer; monoclonal antibodies for medical diagnostic use; monoclonal antibodies for medical use for pain, itch, diabetes, cancer, and inflammation; monoclonal antibodies for therapeutic purposes for the treatment of pain, itch, diabetes, cancer, and inflammation; products containing antibodies for use in medicine for pain, itch, diabetes, cancer, and inflammation; reagents for use in the development of monoclonal antibodies for medical diagnostic purposes; monoclonal antibodies for medical use for diagnostic purposes for pain, itch, diabetes, cancer and inflammation; biological preparations for medical purposes for the treatment of pain, itch, diabetes, cancer, and inflammation; biological products for medical use, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues for the treatment of pain, itch, diabetes, cancer, and inflammation; biological reagents for medical diagnostic purposes for use in molecular biology; biological substances for medical use, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues for the treatment of pain, itch, diabetes, cancer, and inflammation; reagents for use in biological processing for medical diagnostic purposes; reagents for use in biological processing for medical diagnostic purposes for veterinary purposes; therapeutic biological products, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues for the treatment of pain, itch, diabetes, cancer, and inflammation; monoclonal antibody reagents for medical diagnostic use; medical therapeutic agents for the treatment of pain, itch, diabetes, cancer, and inflammation; medical therapeutic drugs for the treatment of pain, itch, diabetes, cancer, and inflammation; animal care products for veterinary use, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues or recombinant proteins for the treatment of pain, itch, diabetes, cancer, and inflammation; biotechnological preparations for veterinary use, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues for the treatment of pain, itch, diabetes, cancer, and inflammation

Pharmaceutical research services; research relating to pharmaceuticals; services for assessing the efficiency of pharmaceuticals, namely, molecular binding, stability, immunogenicity and potency assays; services for assessing the safety of pharmaceuticals, namely, animal model and in-species clinical studies; services for assessing the efficiency of veterinary drugs, namely, molecular binding, stability, immunogenicity and potency assays and proof-of-concept and field studies; veterinary laboratory services; advisory services relating to scientific research, namely, advice in the field of therapeutic biologic drug candidate selection and development; laboratory services, namely, laboratory services for scientific research services and analysis of therapeutic biologic drugs; scientific laboratory services; scientific research; scientific research in the field of pharmacy; biological research; services for assessing the safety of veterinary drugs, namely, animal model and in-species clinical studies; provision of information relating to scientific research, namely, information on the identification and development of therapeutic biologic drug candidates